Current management options for latent tuberculosis: A review

Brianna L. Norton, David P. Holland

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

Original languageEnglish (US)
Pages (from-to)163-173
Number of pages11
JournalInfection and Drug Resistance
Volume5
Issue number1
Publication statusPublished - Dec 1 2012
Externally publishedYes

    Fingerprint

Keywords

  • Interferon-gamma release assay
  • Isoniazid
  • Rifampin
  • Rifapentine
  • Tuberculin skin test

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this